Reviewing Calithera Biosciences Inc. (CALA)’s and Immuron Limited (NASDAQ:IMRN)’s results

This is a contrast between Calithera Biosciences Inc. (NASDAQ:CALA) and Immuron Limited (NASDAQ:IMRN) based on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Calithera Biosciences Inc. 17.07M 12.23 65.11M -1.48 0.00
Immuron Limited N/A 0.00 N/A -0.68 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Calithera Biosciences Inc. and Immuron Limited.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Calithera Biosciences Inc. and Immuron Limited.

Net Margins Return on Equity Return on Assets
Calithera Biosciences Inc. -381.43% -50.5% -44.8%
Immuron Limited 0.00% 0% 0%

Insider and Institutional Ownership

Roughly 68% of Calithera Biosciences Inc. shares are owned by institutional investors while 3.06% of Immuron Limited are owned by institutional investors. 1.31% are Calithera Biosciences Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Calithera Biosciences Inc. -9.12% -9.84% 7.37% 17.36% -2.91% 41.65%
Immuron Limited 2% -27.29% -28.09% -43.44% -55.78% -12.24%

For the past year Calithera Biosciences Inc. had bullish trend while Immuron Limited had bearish trend.

Summary

Immuron Limited beats Calithera Biosciences Inc. on 5 of the 9 factors.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellersÂ’ diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.